The purpose of our study was to evaluate the utilization of stereotactic radiosurgery (SRS) by race in the management of benign and malignant meningioma. The NCDB is a joint project of the American Cancer Society and the Commission on Cancer of the American College of Surgeons, and is a nationwide, comprehensive clinical surveillance resource oncology data set that captures 70% of all newly-diagnosed malignancies in the United States annually. Data for patients meeting the ICD-O-3 criteria for meningioma and undergoing radiation therapy were extracted from the Participant Use File (PUF) 2013 data file encompassing the years 2004 to 2013. Trends of use by race and independent factors related to SRS use were studied. Race categories included White (Wh), Black (Bl), American Indian (AI), Asian (As), and Hawaiian/Polynesian (HP). Statistical analyses were performed on IBM SPSS Statistics version 23.0. Association between SRS use and independent factors was assessed using a general linear model for univariate analysis (UVA), and a linear regression model for multivariate analysis (MVA). A total of 179,498 patients diagnosed with meningioma were identified in the PUF 2013 file. Of these, 17,353 patients underwent RT (56.2% SRS and 43.8% non-SRS). Demographics for this group of patients were: Median age 60, female 70.6%, Wh 83.1%, Bl 13.1%, AI 0.3%, As 3.3%, and HP 0.2%. For patients undergoing SRS, 25.6% of patients were over 70, 95.1% had benign tumors, 70% had tumors <4cm, 80% of patients underwent SRS as monotherapy, and 19.8% of patients underwent combined modality therapy. For the entire population, SRS use increased from 58.8% in 2004 to 62.2% in 2005, and then steadily decreased (48.3% in 2013; p< 0.001). When evaluated by race, Wh patients tended to have the highest rate of SRS use (59.6% in 2004, 64.5% peak in 2005, and 48.2% in 2013), and Bl patients had the lowest rate (53.9% in 2004, 57.7% peak in 2007, and 48.5% in 2013). As patients tended to have the second highest SRS utilization, and detailed analyses for AI and HP patients were limited secondary to small patient numbers. Of the 17 variables evaluated, 10 variables were significant on both UVA and MVA: Year of diagnosis, patient age, insurance status, histology, behavior, tumor size, grade, margin status, facility type and location, and Crowfly distance. SRS utilization in the treatment of meningioma peaked in 2005, and has slowly decreased. Numerous factors were associated with SRS use including demographic, tumor characteristics, and the use of surgery. Race was significant on UVA, with Bl patients being less likely to undergo SRS treatments, but not on MVA. Further research is needed to better understand the causes underlying these observed trends.